ArticleRheumatology international2026
Serum protocadherin 18 as a potential biomarker for antiphospholipid syndrome: a case-control study.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aimed to evaluate the discriminatory capacity of serum Protocadherin 18 (PCDH18) for Antiphospholipid Syndrome (APS), investigate its association with specific clinical and laboratory manifestations. A total of 208 participants were enrolled, including 104 patients with APS, 28 asymptomatic aPL carriers, and 76 healthy donors (HD). Serum PCDH18 levels were quantified using enzyme-linked immunosorbent assay (ELISA). We evaluated the associations of PCDH18 levels with clinical manifestations and laboratory test parameters. The discriminatory capacity was evaluated using Receiver Operating Characteristic (ROC) curve analysis. Serum PCDH18 levels were significantly elevated in APS patients compared to both aPL carriers and HD [97.42 (IQR: 82.48) pg/mL vs. 42.74 (IQR: 52.95) pg/mL, P<0.001; 97.42 (IQR: 52.95) pg/mL vs. 43.92 (IQR: 51.85) pg/mL, P<0.001], with no significant difference between aPL carriers and HD. PCDH18 had moderate value in discriminating APS from aPL carriers (AUC = 0.779, 95% CI: 0.691-0.866). At a cut-off of 98.63 pg/mL, specificity was 100.00% and sensitivity 50.00%, yielding a positive likelihood ratio (LR+) of infinity and a negative likelihood ratio (LR-) of 0.50. For differentiating APS from HD, the AUC was 0.746 (95% CI: 0.674-0.818); at a cut-off of 54.66 pg/mL, sensitivity and specificity were 71.15% and 65.79%, respectively (LR+ = 2.08, LR- = 0.44). When comparing APS with total controls, the AUC was 0.755 (95% CI: 0.690-0.819), with a cut-off of 92.46 pg/mL providing 51.92% sensitivity and 84.62% specificity (LR+ = 3.38, LR- = 0.57). Elevated PCDH18 levels were significantly associated with thrombosis recurrence (OR = 1.02, 95% CI: 1.00-1.05). Serum PCDH18 is elevated in APS patients, demonstrates moderate discriminatory capacity in distinguishing APS from aPL carriers and healthy donors, and correlates with thrombotic recurrence, indicating its potential as an exploratory adjunctive biomarker.
Indexed as
Identifiers
42821147What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.